AzTrials
AzTrials

Pancreatogenic Diabetes MellitusNCT07665710

Prediction of Pancreatogenic Diabetes After Partial Resection of the Pancreas

An observational study of Pancreatogenic Diabetes Mellitus, run by University Medical Centre Ljubljana at 1 site in Slovenia.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The primary aim of the study is to identify clinical, laboratory, imaging, and pathohistological risk factors for the development of pancreatogenic diabetes after partial resection of the pancreas (PRP) and, based on these, to build a predictive model that would enable reliable and accurate identification of patients… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Pancreatogenic Diabetes Mellitus
How many people
150 participants
Where
1 siteSlovenia
Study dates
1 Apr 2026to 1 Apr 2029
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Adult patients undergoing partial pancreatectomy for pancreatic diseases at a tertiary care center, which correspond to inclusion and exclusion criteria.

Who may be able to join

  • age ≥ 18 years
  • planned partial resection of the pancreas
  • absence of known diabetes before the procedure
  • absence of known borderline basal glycemia before the procedure
  • absence of impaired glucose tolerance before the procedure
  • signed written informed consent

Who cannot join

  • known diabetes mellitus before the procedure
  • known borderline basal glycemia before the procedure
  • impaired glucose tolerance before the procedure
  • inability to provide informed consent
  • withdrawal of consent during the course of the study
  • total resection of the pancreas
  • a subsequent decision for conservative treatment (based on clinical characteristics at the time of the surgical procedure)

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Brina Šket Tomšič, MD contact

00 386 1 522 2516

brina.sket@kclj.si

Mojca Lunder, MD, PhD contact

00 386 1 522 2516

mojca.lunder@kclj.si

Slovenia1 site, 1 recruiting
  • University Medical Centre Ljubljana

    Ljubljana, 1000

    Brina Šket Tomšič, 00386 1 522 2516, brina.sket@kclj.si

    Mojca Lunder, 00 386 1 522 2516, mojca.lunder@kclj.si

    Recruiting

Other trials in Slovenia

About this study

The primary aim of the study is to identify clinical, laboratory, imaging, and pathohistological risk factors for the development of pancreatogenic diabetes after partial resection of the pancreas (PRP) and, based on these, to build a predictive model that would enable reliable and accurate identification of patients who will develop pancreatogenic diabetes. A review of the literature shows that there is currently no validated tool available in clinical practice for identifying patients at risk of this type of diabetes after PRP. Etiological differences between type 2 diabetes and pancreatogenic diabetes often lead to late diagnosis, limiting opportunities for timely intervention. The development of a comprehensive predictive model would contribute to a better understanding of the pathophysiology of pancreatogenic diabetes, enable the identification of patients at risk, facilitate tailored clinical monitoring, and allow the implementation of targeted preventive or therapeutic measures in the perioperative period.

Based on a review of the literature and clinical observations, the investigators formulated the following hypotheses:

Read more

H1: Clinical, laboratory, imaging, and pathohistological variables are independently associated with the development of pancreatogenic diabetes after partial pancreatic resection.

H2: A predictive model that allows reliable and accurate identification of patients who will develop pancreatogenic diabetes can be build based on the identified variables (H1).

H3: A comprehensive predictive model in the perioperative period allows more precise identification of patients who will develop pancreatogenic diabetes, and thus more effective risk stratification compared to the use of individual risk factors (variables).

Based on the reviewed literature and our own clinical observations, this constitutes an original contribution to science. The investigators expect that the research will identify key clinical, laboratory, imaging, and pathohistological factors associated with the development of pancreatogenic diabetes after partial pancreatic resection. The development of a clinically useful predictive model that will allow individual risk assessment for the development of pancreatogenic diabetes in patients after partial pancreatic resection is anticipated. A similar comprehensive model has not yet been described in the accessible literature. The research will contribute to a better understanding of metabolic changes and will enable the identification of patients who will develop pancreatogenic diabetes after partial pancreatic resection. The results of the study could provide a basis for improved perioperative monitoring of these patients in the field of pancreatogenic diabetes.

Read the detailed description

Research Protocol:

At the first preoperative examination in the Abdominal Surgery Outpatient Clinic of the University Medical Centre Ljubljana, inclusion and exclusion criteria for the study will be considered and the suitable patients will recieve oral and written explanation about the purpuse, course and nature of the study (day 0). After obtaining written consent from patients, the investigators will collect demographic data (gender, age), data from each participant's medical records (associated diseases, list of regular therapies, etc.) and clinical data on the underlying pancreatic disease (including abdominal CT findings). The anthropometric measurements (body weight and hight), vital sign measurements (blood pressure, pulse) and laboratory markers, that are routinely analyzed before the PRP, will be determined. Additionally, HbA1c, serum fasting insulin and C-peptide will be measured and an oral glucose tolerance test (OGTT) administered,according to a standardized procedure with a standard fasting period. The degree of insulin resistance (HOMA-IR and CGR) will be assessed. Blood analyses will be conducted at the Laboratory of the Clinical Institute of Clinical Chemistry and Biochemistry and the Clinic of Nuclear Medicine of the University Medical Centre Ljubljana.

According to clinical indications, the participants will then be called for the PRP (e.g., distal pancreatectomy, pancreatoduodenectomy, or other form of partial resection), which will be carried out at the Clinical Department of Abdominal Surgery at the University Medical Center in Ljubljana. The pathological examination of the removed part of the pancreas will be undertaken as part of the routine postoperative analysis at the Institute of Pathology, Faculty of Medicine, University of Ljubljana. In the removed pancreatic tissue the proportion of β cells, fat, and fibrous tissue will be assessed during patohistological analysis.

Three months after PRP, which coincides with the regular postoperative check-up with the abdominal surgeon, there will be a follow-up examination in Abdominal Surgery Outpatient Clinic of the University Medical Centre Ljubljana. The same data will be collected as before PRP and HOMA-IR and CGR recalculated. Likewise, patients will undergo a follow-up abdominal CT as part of routine clinical practice, where using a computer program, the volume of tissue removed, as well as the fat and fibrous tissue will be compared to the examination before the PRP. This time point after the PRP was chosen as clinically feasible and methodologically suitable for assessing early postoperative endocrine dysfunction of the pancreas, as it allows monitoring of metabolic changes after resection with minimal additional burden on the patients. The three-month follow-up also reduces the impact of long-term confounding factors, such as the progression of malignant disease, cachexia, prolonged systemic oncological treatment, and loss of patients from follow-up. When interpreting the results, the investigators will nevertheless take into account postoperative complications, the introduction of chemotherapy, the use of glucocorticoids, nutritional status, and other factors that can affect glucose metabolism.

All the obtained data will be statistically analyzed, and a statistical predictive model for the occurrence of pancreatogenic diabetes after partial pancreatic resection will be constructed.To reduce the possibility of variability between different observers, histopathological analyses will be performed by one pathologist and CT analyses by one radiologist.

Statistical Methods:

All approaches and methods presented below are based on the TRIPOD+AI guidelines for statistical analysis and preparation of predictive models in the field of biomedicine. The sample size was estimated based on recommendations for the development of clinical predictive models. With the expected incidence of pancreatogenic diabetes, which according to PRP is approximately 20-30%, the investigators expect about 30-45 events. Such a number of events allows the inclusion of a limited number of predictors in a multivariable statistical model while taking into account the ratio of the number of events to the number of predictive variables. At the same time, the number of participants also depends on the number of partial pancreatic resections at the Clinical Department of Abdominal Surgery at the University Medical Center Ljubljana. It was also considered that some patients will drop out of the study (either due to the prognosis of the underlying disease or other factors), so the planned sample size will be increased by 10%. Therefore it is estimated that at least 150 patients has to be included in the study.

The analytical workflow consists of three main components: data preprocessing, statistical model building, and interpretation of model results. In the initial phase of analysis, a systematic understanding of the data will be carried out, which includes a review of all collected clinical, demographic, and laboratory measurement variables. Numerical variables will be analyzed using basic descriptive statistical indicators (mean, standard deviation, median, interquartile range), with the normality of the distribution assessed using appropriate statistical tests and graphical methods. Categorical variables will be summarized with frequencies and percentages. Missing variable values will be addressed according to their pattern of occurrence. If the proportion of missing data is ≤ 10%, appropriate multivariate methods for imputing missing values will be used; otherwise, a complete case analysis will be performed. The pre-selection of measurable variables will be carried out based on a combination of clinical judgment, review of the existing literature, and statistical analysis. In the initial phase, the variables will be evaluated using univariate statistical methods in relation to the dependent variable. Variables that reflect clinical relevance or statistically significant or borderline significant association with the outcome will be included in the subsequent analysis.The core of the task involves the development and evaluation of a statistical model for predicting the value of the dependent variable . Supervised machine learning approaches will be used; test standard algorithms for pre-symbolic and symbolic learning, including logistic regression, support vector machines, random forests, and the XGBoost approach. In order to further reduce the risk of overfitting the predictive model and to improve its stability and interpretability, the number of predictors will be further limited using wrapper and embedded approaches. The built models will be evaluated (solution stability and generalizability) according to the standard 10-fold cross-validation scheme. All approaches will be implemented in accordance with TRIPOD guidelines. The importance of individual predictors and their association with clinical parameters will be explained using the SHAP (SHapley Additive exPlanations) approach. The quality of the models will be evaluated using standard metrics for balanced data, including discrimination, calibration parameters, and (clinical) decision curve analysis . All analyses will be implemented in the R programming language. The use of the predictive model does not pose any additional interventions or burdens for the participants, as it is based solely on a retrospective analysis of collected data.

Keywords
Partial Pancreatectomy, Pancreatogenic Diabetes, Prediction Model, Pancreas Volume, C-peptide, HOMA-IR

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT07665710
Study groupRoleWhat they receive
Patients Undergoing Partial PancreatectomyThis cohort includes adult patients undergoing partial pancreatectomy for various pancreatic diseases. Inclusion criteria: age ≥ 18 years, planned partial resection of the pancreas, absence of known diabetes mellitus, borderline basal glycemia, or impaired glucose tolerance before the procedure, signed written informed consent. Criteria for non-inclusion: known diabetes, borderline basal glycemia or impaired glucose tolerance before surgery (even if confirmed by OGTT before the procedure), inability to provide informed consent. Participants are prospectively followed to assess metabolic changes and the development of pancreatogenic diabetes. No experimental interventions are administered as part of the study; all patients receive standard clinical care. Data collection includes clinical, biochemical, imaging, and histopathological parameters.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Development of pancreatogenic diabetes

    Pancreatogenic diabetes will be assessed based on standard diagnostic criteria using oral glucose tolerance test.

    Measured: 3 months after surgery

Secondary outcomes (5)
  1. Insulin Resistance

    Insulin resistance will be evaluated using the HOMA-IR index calculated from fasting glucose and insulin levels.

    Measured: Baseline to 3 months after surgery

  2. Beta Cell Function

    Beta-cell function will be assessed using C-peptide and glucose measurements.

    Measured: Baseline to 3 months after surgery

  3. Prediction Model Performance

    Everything will be implemented according to TRIPOD+AI. The predictive accuracy of the developed model will be evaluated using receiver operating characteristic (ROC) analysis.

    Measured: At 3 months after surgery

  4. Patohistology of the Pancreas

    lipomatosis, fibrosis, beta cell density of the pancreas

    Measured: immediately after the resection of the pancreas

  5. CT of the abdomen

    Volume of the pancreas and fat distribution in the pancreas

    Measured: before the resection of the pancreas and 3 months after the resection

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Jun 2026
  2. Study start1 Apr 2026
  3. Primary completion1 Apr 2029 (estimated)
  4. Study completion1 Apr 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
150 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07665710
Sponsor's protocol ID
PRADO
Status last verified
Jul 2026
First submitted
9 Jun 2026
Last updated
16 Jul 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: De-identified IPD will include demographic and clinical baseline data, perioperative surgical variables, metabolic and laboratory parameters (including glucose, HbA1c, insulin, C-peptide, OGTT-derived indices such as HOMA-IR), selected imaging-derived variables, histopathological findings of pancreatic tissue, and 3-month postoperative outcomes including diagnosis of pancreatogenic diabetes.

Publications

  • Lundberg S, Lee SI. A Unified Approach to Interpreting Model Predictions [Internet]. arXiv; 2017 [citirano 8. marec 2026]. Dostopno na: https://arxiv.org/abs/1705.07874 doi:10.48550/ARXIV.1705.07874

  • Collins GS, Moons KGM, Dhiman P, Riley RD, Beam AL, Van Calster B, Ghassemi M, Liu X, Reitsma JB, van Smeden M, Boulesteix AL, Camaradou JC, Celi LA, Denaxas S, Denniston AK, Glocker B, Golub RM, Harvey H, Heinze G, Hoffman MM, Kengne AP, Lam E, Lee N, Loder EW, Maier-Hein L, Mateen BA, McCradden MD, Oakden-Rayner L, Ordish J, Parnell R, Rose S, Singh K, Wynants L, Logullo P. TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods. BMJ. 2024 Apr 16;385:e078378. doi: 10.1136/bmj-2023-078378.

    PubMed 38626948
  • Imamura S, Niwano F, Babaya N, Hiromine Y, Matsumoto I, Kamei K, Yoshida Y, Taketomo Y, Yoshida S, Takeyama Y, Noso S, Maeda N, Ikegami H. High Incidence of Diabetes Mellitus After Distal Pancreatectomy and Its Predictors: A Long-term Follow-up Study. J Clin Endocrinol Metab. 2024 Feb 20;109(3):619-630. doi: 10.1210/clinem/dgad634.

    PubMed 37889837
  • Riley RD, Ensor J, Snell KIE, Harrell FE Jr, Martin GP, Reitsma JB, Moons KGM, Collins G, van Smeden M. Calculating the sample size required for developing a clinical prediction model. BMJ. 2020 Mar 18;368:m441. doi: 10.1136/bmj.m441. No abstract available.

    PubMed 32188600
  • Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015 Feb 26;372(9):793-5. doi: 10.1056/NEJMp1500523. Epub 2015 Jan 30.

    PubMed 25635347
  • Steyerberg EW. Clinical Prediction Models: A Practical Approach to Development, Validation, and Updating. 2nd ed. Cham: Springer International Publishing AG; 2019. 1 str. (Statistics for Biology and Health)

  • Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004 Jun;27(6):1487-95. doi: 10.2337/diacare.27.6.1487.

    PubMed 15161807
  • Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985 Jul;28(7):412-9. doi: 10.1007/BF00280883.

    PubMed 3899825
  • Hope SV, Jones AG, Goodchild E, Shepherd M, Besser RE, Shields B, McDonald T, Knight BA, Hattersley A. Urinary C-peptide creatinine ratio detects absolute insulin deficiency in Type 2 diabetes. Diabet Med. 2013 Nov;30(11):1342-8. doi: 10.1111/dme.12222. Epub 2013 Jun 12.

    PubMed 23659458
  • Jones AG, Hattersley AT. The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabet Med. 2013 Jul;30(7):803-17. doi: 10.1111/dme.12159.

    PubMed 23413806
  • Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation. Geneva, Switzerland: World Health Organization; 2006.

  • Shirakawa S, Matsumoto I, Toyama H, Shinzeki M, Ajiki T, Fukumoto T, Ku Y. Pancreatic volumetric assessment as a predictor of new-onset diabetes following distal pancreatectomy. J Gastrointest Surg. 2012 Dec;16(12):2212-9. doi: 10.1007/s11605-012-2039-7. Epub 2012 Sep 28.

    PubMed 23054900
  • Wu L, Nahm CB, Jamieson NB, Samra J, Clifton-Bligh R, Mittal A, Tsang V. Risk factors for development of diabetes mellitus (Type 3c) after partial pancreatectomy: A systematic review. Clin Endocrinol (Oxf). 2020 May;92(5):396-406. doi: 10.1111/cen.14168. Epub 2020 Feb 18.

    PubMed 32017157
  • Almeida RR, Lo GC, Patino M, Bizzo B, Canellas R, Sahani DV. Advances in Pancreatic CT Imaging. AJR Am J Roentgenol. 2018 Jul;211(1):52-66. doi: 10.2214/AJR.17.18665. Epub 2018 Apr 9.

    PubMed 29629796
  • Sofue K, Ueshima E, Masuda A, Shirakawa S, Zen Y, Ueno Y, Tsujita Y, Yamaguchi T, Yabe S, Tanaka T, Inomata N, Toyama H, Fukumoto T, Kodama Y, Murakami T. Estimation of pancreatic fibrosis and prediction of postoperative pancreatic fistula using extracellular volume fraction in multiphasic contrast-enhanced CT. Eur Radiol. 2022 Mar;32(3):1770-1780. doi: 10.1007/s00330-021-08255-4. Epub 2021 Oct 12.

    PubMed 34636963

Questions about this trial

What is this clinical trial studying?

An observational study of Pancreatogenic Diabetes Mellitus, run by University Medical Centre Ljubljana at 1 site in Slovenia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 16 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Slovenia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Brina Šket Tomšič, MD (00 386 1 522 2516, brina.sket@kclj.si), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Development of pancreatogenic diabetes (time frame: 3 months after surgery). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07665710, which also lists 28 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jul 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in